SomaGenics is a privately held company that develops innovative RNA technologies for therapeutic and diagnostic uses. SomaGenics' lead therapeutic program, against hepatitis C virus, has successfully completed efficacy evaluations in preclinical animal models and is ready for clinical development.
SomaGenics Secures $1.8M in Funding From NIH to Further Develop the Real-Seq® Technology Platform
SANTA CRUZ, Calif., Oct. 4, 2016 /PRNewswire/ — SomaGenics has been awarded a $1.8M two-year NIH SBIR Phase II grant to further develop its RealSeq®–AC technology for next-generation sequencing (NGS) of small RNAs such as microRNA. Real-Seq®-AC dramatically reduces bias in small RNA sequencing libraries compared to commercially available library construction methods. "Bias reduction is […]
SANTA CRUZ, Calif., July 28, 2016 /PRNewswire/ — SomaGenics Inc. today announced that it has signed a licensing agreement with Rubicon Genomics, Inc. for commercialization of SomaGenics' RealSeq®-AC library preparation technology for sequencing small RNAs, including micro-RNAs and small fragments of large RNAs. Further terms of the agreement were not disclosed. The RealSeq®-AC platform is a […]
SANTA CRUZ, Calif., Feb. 9, 2016 /PRNewswire/ — Somagenics has been awarded a second phase I SBIR grant from NIH to develop its resQ-RNATM technology for quantitative real-time PCR of fragmented RNA samples. Fragmentation of RNA is a particular problem in tissue samples that have been preserved and stored (e.g., formaldehyde-fixed, paraffin-embedded [FFPE] specimens) or collected […]
SANTA CRUZ, Calif., Oct. 7, 2015 /PRNewswire/ — SomaGenics, Inc. today announced the launch of its novel miR-ID® platform and assays for detecting miRNA using a circularization-based RT-qPCR method. miR-ID® is highly sensitive, uses single-dye detection, and can discriminate miRNA isoforms with single nucleotide differences at any position along the molecule. The technology works well with all sample […]
SomaGenics Awarded 2-Year NIH Grant to Develop NGS microRNA Library Technology
SANTA CRUZ, Calif., April 28, 2015 /PRNewswire/ — SomaGenics has been awarded a two-year NIH grant to develop its novel RealSeq™–T technology for targeted next-generation sequencing (NGS) of small RNAs such as microRNA. There is increasing interest in using NGS for miRNA biomarker discovery from biofluids such as blood plasma as well as for miRNA expression […]
SANTA CRUZ, Calif., Dec. 18, 2014 /PRNewswire/ — SomaGenics has recently been awarded $2,275,000 in Small Business Innovation Research (SBIR) grants from the NIH to further develop and expand its RNA-based technologies in the areas of wound healing, hepatitis delta virus (HDV) therapeutics, microRNA (miRNA) expression profiling, and next-generation sequencing. SomaGenics' wound healing program is focused […]
SomaGenics Awarded Four Patents Spanning Its miRNA and RNAi Programs
SANTA CRUZ, Calif., Dec. 16, 2014 /PRNewswire/ — SomaGenics, Inc. has had four patents covering various aspects of its small RNA platform technologies issued or allowed by the US and European Patent Offices. Two of these patents cover short hairpin RNA (shRNA) and small interfering RNA (siRNA): US Patent No. 8,779,115 B2 covers methods, compositions and […]
SANTA CRUZ, Calif., Nov. 12, 2012 /PRNewswire/ — SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, has been awarded US Patent No. 8,283,460 for key aspects of the company's sshRNA therapeutic platform. sshRNAs are small synthetic stem-loop (or hairpin) RNAs that the company's researchers have shown to be highly potent in knocking down target RNAs […]
SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform
SANTA CRUZ, Calif., July 24, 2012 — SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, announced the publication of a study reporting the mechanism of action of its sshRNAs, the class of molecules that forms the basis of the company's therapeutic platform. sshRNAs are small synthetic stem-loop (or hairpin) RNAs that the company's researchers […]
SomaGenics’ sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus
SANTA CRUZ, Calif., Sept. 20, 2011 — SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, presented exciting data on the efficacy of RNA interference (RNAi) therapeutics against Hepatitis C virus (HCV) based on the company's sshRNA platform. SomaGenics, along with its collaborators at Tekmira Pharmaceuticals and Roche, presented the results in a poster entitled […]
